A delicate dance: Balancing cancer care and pregnancy.
The American Society of Clinical Oncology (ASCO) has released a crucial guideline, published in the Journal of Clinical Oncology, addressing the complex issue of managing cancer in pregnant patients. With only one in 1000-2000 pregnancies facing a new cancer diagnosis, this topic demands our attention and understanding.
Dr. Mikkael A. Sekeres, Chief of Hematology at Sylvester Comprehensive Cancer Center, emphasizes the depth of this challenge. "It's a rare occurrence, but the implications are profound. We must carefully navigate the needs of both the mother and the fetus."
The guideline tackles critical questions, offering evidence-based recommendations. However, the evidence itself is often limited, relying on retrospective studies and case reports. Despite this, the authors believe the recommendations are strong, providing valuable real-world insights.
Dr. Ann H. Partridge, Director of the Adult Survivorship Program at Dana-Farber Cancer Institute, highlights the key considerations: understanding the patient's preferences, weighing disease and treatment risks, and evaluating the impact on the fetus. "We must be honest about what we know and don't know," she adds.
Key recommendations include a multidisciplinary approach, with pharmacists playing a vital role in developing personalized treatment plans. Patient autonomy is emphasized, especially in emergency situations where immediate cancer treatment may be necessary, potentially impacting the pregnancy.
One of the most controversial aspects is the use of drugs with unknown teratogenic potential. Dr. Sekeres notes the limitations of the available evidence, stating, "Study designs offer insights, but bias, small samples, and heterogeneity are inherent challenges."
Dr. Partridge acknowledges the uncertainty surrounding newer therapies like bispecific agents and antibody-drug conjugates, saying, "The risks are not well understood, making this a complex area to navigate."
This guideline provides a framework, but many questions remain. How can we improve our understanding of these therapies' impact on pregnant patients? What are your thoughts on this delicate balance between cancer care and fetal health? Share your insights in the comments below!
